Knowledge Library

Hepatobiliary Disease Platform

Hepatobiliary Disease Platform All-encompassing hepatobiliary disease models: NAFLD, NASH, Fibrosis, Cirrhosis, PBC/PSC, ALD, and more Comprehensive hepatic tissue bank and transcriptomics database Professional quantitative analysis in pathology Histopathology Laboratory CAP-certified pathology laboratory Tissue processor Embedding center Cyostats Microtomes Staining workstation IHC & ISH stainer Laser-scanning confocal microscope HALO-AI quantitative histopathology

Resource Type: Brochure
Resource Topic: in vivo Pharmacology Liver Diseases NASH

VIEW

Fibrosis Models in Mice and Rats

Selecting preclinical in vivo models that are reflective of clinical outcome is a key challenge in the development of new therapies to treat fibrotic diseases.  To accelerate research focused on pulmonary, renal, and liver fibrosis, WuXi AppTec has established a series of in vivo models supported with anti-fibrotic efficacy data.  Our platform also includes a …Read More >

Resource Type: Presentation
Resource Topic: Autoimmune and Inflammatory Diseases Liver Diseases NASH Respiratory Diseases

VIEW

Translational Pharmacology of CNS and Metabolic Disorders for Testing New Modality Therapies

Animal studies may provide a close approximation to humans when addressing the key challenge of clinical translatability. In the preclinical setting, new insights into disease models and mechanisms are crucial to efficacy studies. In this webinar, Dr. Deming Xu, Chief Pharmacologist, Executive Director, and Head of In Vivo Pharmacology of WuXi AppTec Discovery Biology will …Read More >

Resource Type: Webinar
Resource Topic: Cardiovascular & Metabolic Diseases Central Nervous System & Pain in vivo Pharmacology Metabolic Diseases NASH Oligonucleotides

VIEW

Case Study: Clinically Relevant NASH Animal Model

In this case study, we demonstrate clinical relevance of the HFD+CCL4 (high-fat diet and carbon tetrachloride) NASH animal model. Improvement of hepatic fibrosis has been a challenging endpoint in NASH clinical trials and selecting animal models that show anti-fibrotic efficacy has been equally challenging for the preclinical development of new NASH drugs.  Our findings indicate …Read More >

Resource Type: Case Study Latest Science
Resource Topic: in vivo Pharmacology Liver Diseases Metabolic Diseases NASH

VIEW

WuXi AppTec Discovery Services

Delivering comprehensive end-to-end solutions for creating, identifying, and supporting preclinical candidates, from discovery to development, with our integrated chemistry and biology research platforms.  

Resource Type: Brochure
Resource Topic: Antibodies Antibody Drug Conjugate Autoimmune and Inflammatory Diseases Biochemical Assays Biomarkers Biophysical Assays Candidate Selection CAR-T Cell Cardiovascular & Metabolic Diseases Cell Therapies Cell-based Assays Cells and Protein Science Central Nervous System & Pain Chemical Biology and Proteomics Dermatology Discovery Chemistry DNA-Encoded Library (DEL) DRUG DISCOVERY AND INNOVATION Fragment-Based Drug Discovery Gene Therapies High-throughput screening (HTS) Hit Finding Hit-to-Lead Immunology in silico services in vitro biology in vivo Pharmacology in vivo Toxicology Infectious Diseases Lead Optimization Liver Diseases Mass Spectrometry-based Assays Metabolic Diseases NASH Oligonucleotides Oncology Oncolytic Viruses Ophthalmology Phenotypic Assays Quantum Mechanics Rare Diseases Respiratory Diseases Safety and Early Toxicity Screening Libraries Screening Services Small Molecules Structural Biology Target Identification and Validation Target-Specific Assays Targeted Protein Degradation TECHNOLOGY PLATFORMS THERAPEUTIC AREAS THERAPEUTIC MODALITIES Tumor Models

VIEW

NASH Animal Models and their Clinical Relevance – Quantitative Histopathology of Hepatic Fibrosis

Resource Type: Webinar
Resource Topic: Biomarkers Lead Optimization Liver Diseases Metabolic Diseases NASH

VIEW

Quantitative Histopathology of Fibrosis in an Animal Model of NASH

The hepatic fibrosis has been the most challenging aspect in the animal models for nonalcoholic steatohepatitis (NASH). Although it could induced by nutritional (high-fat died with high cholesterol, methionine and choline deficient diet, etc), chemical (carbon tetrachloride, thioacetamide, α-naphthylisothiocyanate etc.), and surgical (bile duct ligation) means, the clinical relevance of the resulting fibrosis remains an …Read More >

Resource Type: Article Blog
Resource Topic: Biomarkers Candidate Selection Liver Diseases Metabolic Diseases NASH

VIEW


Resource Topics
× peptide, amino acid

Contact An Expert Today!